InsiderSignal.AI

InsiderSignal.ai

TVTX - Travere Therapeutics, Inc.

Insider Sale by Baynes Roy D. (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Baynes Roy D., serving as Dir at Travere Therapeutics, Inc. (TVTX), sold 32,750 shares at $41.29 per share, for a total transaction value of $1,352,130.00. Following this transaction, Baynes Roy D. now holds 37,500 shares of TVTX.

This sale represents a 47.00% decrease in Baynes Roy D.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, April 14, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 16, 2026, 2 days after the trade was made.

Travere Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Baynes Roy D.

Baynes Roy D.

Dir

Roy D. Baynes, M.D., Ph.D., is a Director at Travere Therapeutics, Inc. (TVTX) since 2016.[[1]](https://theorg.com/org/travere-therapeutics/org-chart/roy-d-baynes)[[4]](https://arcnouvel.com/dr-roy-baynes/) He holds degrees including an MB.BCh., M.Med., and Ph.D. from the University of Witwatersrand in South Africa, where he also completed medical training in hematology and oncology at Johannesburg Hospital.[[1]](https://theorg.com/org/travere-therapeutics/org-chart/roy-d-baynes)[[3]](https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-appoints-drug-development-expert-roy-d-baynes/) Dr. Baynes has a distinguished career in pharmaceutical leadership, currently serving as Executive Vice President and Chief Medical Officer at Eikon Therapeutics, following roles as Senior Vice President and Head of Global Clinical Development and Chief Medical Officer at Merck, Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at Gilead Sciences, and Vice President of Global Clinical Development for Hematology/Oncology at Amgen.[[1]](https://theorg.com/org/travere-therapeutics/org-chart/roy-d-baynes)[[2]](https://www.terrapinn.com/virtual/advanced-therapies/speaker-roy-BAYNES.stm)[[3]](https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-appoints-drug-development-expert-roy-d-baynes/)[[4]](https://arcnouvel.com/dr-roy-baynes/)[[5]](https://www.eikontx.com/team/roy-baynes/) Earlier, he was the Charles Martin Professor of Cancer Research at Wayne State University’s Barbara Ann Karmanos Cancer Institute.[[1]](https://theorg.com/org/travere-therapeutics/org-chart/roy-d-baynes) He has authored over 150 publications and serves on boards including Nurix Therapeutics and Natera, Inc.[[1]](https://theorg.com/org/travere-therapeutics/org-chart/roy-d-baynes)[[3]](https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-appoints-drug-development-expert-roy-d-baynes/)[[4]](https://arcnouvel.com/dr-roy-baynes/)

View full insider profile →

Trade Price

$41.29

Quantity

32,750

Total Value

$1,352,130.00

Shares Owned

37,500

Trade Date

Tuesday, April 14, 2026

3 days ago

SEC Filing Date

Thursday, April 16, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Travere Therapeutics, Inc.

Company Overview

No company information available
View news mentioning TVTX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5693653

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime